These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32946293)

  • 1. Creating a Health Utility Value for Birdshot Chorioretinopathy.
    Sekaran A; Shamdas M; Barry RJ; Denniston AK; Murray PI
    Ocul Immunol Inflamm; 2022 Jan; 30(1):73-80. PubMed ID: 32946293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.
    Au Eong KG; Chan EW; Luo N; Wong SH; Tan NW; Lim TH; Wagle AM
    Eye (Lond); 2012 Mar; 26(3):379-88. PubMed ID: 22222257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrelationships between heath utility measurements, disease activity and psychological factors in Behçet's disease.
    Murray PI; Sekaran A; Javidi H; Situnayake D
    Gen Hosp Psychiatry; 2021; 70():103-108. PubMed ID: 33799105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
    Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China.
    Liu L; Li S; Zhao Y; Zhang J; Chen G
    Qual Life Res; 2018 May; 27(5):1323-1333. PubMed ID: 29492743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
    Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C
    Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with uveitis.
    Shamdas M; Bassilious K; Murray PI
    Br J Ophthalmol; 2019 Sep; 103(9):1284-1288. PubMed ID: 30361275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting and valuing one's own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition.
    Ernstsson O; Burström K; Heintz E; Mølsted Alvesson H
    Health Qual Life Outcomes; 2020 Dec; 18(1):388. PubMed ID: 33334348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
    Li S; Wang M; Liu L; Chen G
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility values in the visually impaired: comparing time-trade off and VisQoL.
    Gothwal VK; Bagga DK
    Optom Vis Sci; 2013 Aug; 90(8):843-54. PubMed ID: 23628757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population.
    Kim SH; Lee SI; Jo MW
    Qual Life Res; 2017 Dec; 26(12):3387-3397. PubMed ID: 28801862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.